Acute Myelogenous Leukemia

Overview of AML.- Approaching the Treatment of AML from a Biological Perspective.- Molecular Foundations of AML Pathogenesis and Physiology.- Aberrant Transcription Factors in AML.- Myelodysplasia-Related AML.- Therapy-related AML.- The DNA Damage Response, DNA Repair, and AML.- Altered Apoptosis in AML.- Drug Resistance Transporters in AML.- Translating Biology into Clinical Application.- Impact of Cytogenetics on Clinical Outcome in AML.- APL: A Classic Tale of Bench to Bedside.- Molecular Therapeutics of AML: Selected Targeted Approaches.- Emerging Therapeutics for AML.- FLT3: A Prototype Receptor Tyrosine Kinase Target in AML.- Farnesyl Transferase Inhibitors in the Therapy of AML.- Modulating Gene Expression as a Therapeutic Approach in the Treatment of AML.- Differentiation Therapy in AML.- Stem Cell Transplantation for AML.- Tumor Vaccines in Leukemia.- Special Challenges.- Treatment, Outcomes, and Challenges of Newly Diagnosed AML in Children and Adolescents.- AML in Older Adults.- Dameshek Smiles: Molecular Clues to the Chronic Myeloproliferative Disorders Unmasked.- New Designs for Clinical Trials.

From the reviews:

"...warmly recommend this book as a comprehensive, up-to-date, and detailed yet concise source of information about AML." -The New England Journal of Medicine

"Acute Myelogenous Leukemia, edited by Judith E. Karp, MD, of Johns Hopkins University, is a multiauthored textbook directed towards the hematologist managing acute leukemia ... . It focuses on new approaches, both practical and theoretical, based on laboratory data as well as clinical studies. ... This textbook includes up-to-date, well-referenced chapters ... . It is a welcomed edition to provide specific information and reference data for hematologists who specialize in AML management." (Barry Cooper, Baylor University Medical Center Proceedings, Vol. 21 (1), 2008)

"The book begins with an overview of the disease and ends with a chapter on some of the particular challenges faced by clinicians ... . For clinicians involved in investigation of new agents, there is considerable usefulness ... . In Acute Myelogenous Leukemia, the reader will find reviews of some of the newer agents and treatment strategies for this uncommon but devastating disease. In addition, this is a reliable source for thorough and clearly written explanations of the scientific development of these new agents." (Laura C. Michaelis, Journal of the American Medical Association, November, 2007)